Etizolam

CAS No. 40054-69-1

Etizolam( Y-7131 | AHR 3219 )

Catalog No. M19451 CAS No. 40054-69-1

Etizolam is a selective platelet-activating factor (PAF) antagonist.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Etizolam
  • Note
    Research use only, not for human use.
  • Brief Description
    Etizolam is a selective platelet-activating factor (PAF) antagonist.
  • Description
    Etizolam is a selective platelet-activating factor (PAF) antagonist.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    Y-7131 | AHR 3219
  • Pathway
    Others
  • Target
    Platelet aggregation
  • Recptor
    platelet-activating factor (PAF)
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    40054-69-1
  • Formula Weight
    342.85
  • Molecular Formula
    C17H15ClN4S
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:25 mg/mL (72.9 mM);Ethanol:58 mg/mL (169.2 mM);Water:<1 mg/mL
  • SMILES
    CCC1=CC2=C(S1)N1C(C)=NN=C1CN=C2C1=CC=CC=C1Cl
  • Chemical Name
    7-(2-Chlorophenyl)-4-ethyl-13-methyl-3-thia-181112-tetraazatricyclo[8.3.0.026]trideca-2(6)471012-pentaene

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.O'Connor LC Torrance HJ McKeown DA.J Anal Toxicol. 2016 Mar;40(2):159-61.
molnova catalog
related products
  • Dextran

    Dextran (Dextran 40) has an inhibitory effect on platelet aggregation and coagulation factors, and is used as an agent for increasing plasma volume.

  • NMS-E973

    NMS-E973 is a potent and selective Hsp90 inhibitor with DC50 of <10 nM for Hsp90 binding, no activiy against a panel of 52 diverse protein kinases.

  • ENFENAMIC ACID

    Enfenamic acid is a platelet aggregation inhibitor and with antirheumatic.Dose-matched comparison between zinc-salt of enfenamic acid and the parent compound was carried out in experimentally wounded male albino rats bearing either sutured incision, dead-space or excision wounds.